EBD Group is part of the KNect365 of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
 
BioPharm America 2014 EBD Group MassBio
Share/Follow Us
Share this:
Follow this event:

Videos


Interview with Baiju Shah, BioMotiv Interview with Baiju Shah, BioMotivSeptember 16, 2015Joe Haas from “The Pink Sheet” interviewed Baiju Shah, CEO of BioMotiv, an accelerator of biotechnological research from the laboratory into drug development. View session here View session here
Interview with Sarah Frew, University of Pennsylvania Interview with Sarah Frew, University of PennsylvaniaSeptember 16, 2015Formerly with Genzyme and Tetralogic, U. Penn’s Sarah Frew talked about opportunities for technology transfer from academic research to the private sector. View session here View session here
Genome editing Genome editingSeptember 17, 2015We have seen exciting progress in the field of gene editing, but how are these advances being applied to cell therapy and disease modification? View session here View session here
Gene and cell therapy
Gene and cell therapy September 17, 2015Gene therapy is transforming the way we treat diseases. This panel discusses the latest industry advances, including new partnerships and regulatory issues. View session here View session here
The evolution of the Regen Med ecosystem: What's required for its growth and sustainability? The evolution of the Regen Med ecosystem: What's required for its growth and sustainability?September 17, 2015Panelists discuss the need for an integrated approach to building the necessary infrastructure for success in innovative biotech and regenerative medicine. View session here View session here
Interview with Christopher Viehbacher, Gurnet Point Capital Interview with Christopher Viehbacher, Gurnet Point CapitalSeptember 15, 2015Christopher Viehbacher, managing partner at Gurnet Point Capital and formerly the CEO of Sanofi, discusses the current dealmaking environment in the biopharmaceutical industry. View session here View session here
Interview with Jeremy Levin, Ovid Therapeutics Interview with Jeremy Levin, Ovid TherapeuticsSeptember 15, 2015Ovid Therapeutics CEO Jeremy Levin, formerly with BMS and most recently the CEO of Teva Pharmaceuticals discusses the trend of big pharma brainpower moving to smaller firms. View session here View session here
Immuno-oncology: New advances + new targets + new partnerships = new cures?
Immuno-oncology: New advances + new targets + new partnerships = new cures? September 15, 2015Big pharma has a strong foothold in immuno-oncology, but with new biotechs coming up with novel platforms and technologies, the field is more exciting now than ever before. View session here View session here
Externalizing R&D, building efficient pharma Externalizing R&D, building efficient pharmaSeptember 15, 2015While trying to maintain a continuous number of potential products, big pharma has had to adjust their acquisition and investment strategy due to declining R&D productivity. View session here View session here
Rare diseases: The new norm? Rare diseases: The new norm?September 15, 2015Panelists share insights on the evolving landscape in rare diseases and discuss the importance of patient engagement and cross-sector collaborations in addressing the opportunities. View session here View session here
Biomarkers and precision medicine
Biomarkers and precision medicine September 15, 2015Panelists discuss how the future of biomarkers and personalized medicine will impact R&D decisions and ultimately benefit patients. View session here View session here
Giving up the corporate jet and going back to the trenches: Insights from biotech disrupters
Giving up the corporate jet and going back to the trenches: Insights from biotech disrupters September 15, 2015These industry heavy hitters have successfully led and exited large corporations and are now investing their experience by leading the charge at small companies. View session here View session here
Interview with Eric Halioua, Promethera Biosciences Interview with Eric Halioua, Promethera BiosciencesSeptember 23, 2014Eric Halioua, CEO of Promethera Biosciences, speaks with partnering360:Insight on their cell therapy products to treat liver diseases affecting children and adults. View session here View session here
Interview with Roger Pomerantz, Seres Health Interview with Roger Pomerantz, Seres HealthSeptember 23, 2014Roger Pomerantz, President and CEO of Seres Health, a 2014 Fierce 15 winning company, shares Seres’ vision and their pursuit of developing drugs to treat diseases of the microbiome. View session here View session here
All innovation roads lead to Massachusetts: Pharma's approach to the Boston biotech cluster
All innovation roads lead to Massachusetts: Pharma's approach to the Boston biotech cluster September 24, 2014Undoubtedly, Boston is one of the most fertile biotech breeding grounds in the world. The leaders of several Boston R&D centers discuss their approach to accessing innovation. View session here View session here
The nearest exit may be behind you: The story of CoStim Pharmaceuticals
The nearest exit may be behind you: The story of CoStim Pharmaceuticals September 23, 2014In early 2014, CoStim was acquired by Novartis. In this session, co-founders, investors and Novartis share the company's story, from vision and formation through exit and beyond. View session here View session here
Clinical outlook for new immuno-oncology treatments Clinical outlook for new immuno-oncology treatmentsSeptember 22, 2014The clinical pipeline for new cancer immunotherapies is growing with new technologies targeting almost the entire spectrum of cancer indications. View session here View session here
State of the Industry: A focus on the financial landscape in the life sciences
State of the Industry: A focus on the financial landscape in the life sciences September 22, 2014Bruce Booth of Atlas Venture leads this plenary discussion from BioPharm America 2014 with leading investors in the biotech start-up space giving their predictions for 2015. View session here View session here
Developing a sustainable commercial model: Can we devise a pricing system for advanced therapies with multiple winners? Developing a sustainable commercial model: Can we devise a pricing system for advanced therapies with multiple winners?September 22, 2014Despite the interest and enthusiasm around the therapeutic potential for advanced therapies in a variety of indications, the pricing question remains unanswered. View session here View session here
Getting real: Biopharma innovation and its impact on patients Getting real: Biopharma innovation and its impact on patientsSeptember 22, 2014Leading biopharma executives discuss how changes in the overall healthcare market are affecting their corporate strategies in addressing diseases. View session here View session here
Interview with Annalisa Jenkins, Dimension Therapeutics Interview with Annalisa Jenkins, Dimension TherapeuticsSeptember 22, 2014In an interview at BioPharm America 2014 in Boston on September 22, John Carroll, Editor-in-Chief of FierceBiotech, speaks with Annalisa Jenkins, the new CEO of Dimension Therapeutics, a 2014 Fierce 15 biotech winner. View session here View session here
Interview with Jeffrey Stein, Cidara Therapeutics Interview with Jeffrey Stein, Cidara TherapeuticsSeptember 22, 2014Jeffrey Stein, CEO of Cidara Therapeutics, a 2014 Fierce 15 biotech winner, discusses recent incentives in the FDA and Cidara’s efforts in the long-neglected anti-fungal arena. View session here View session here
Interview with Ankit Mahadevia, Spero Therapeutics Interview with Ankit Mahadevia, Spero TherapeuticsSeptember 22, 2014Ankit Mahadevia, CEO of Spero Therapeutics and a 2014 Fierce 15 winner discusses the value of Spero’s lead technologies and the challenges involved in the development of novel therapies. View session here View session here
Interview with Gary Nabel, Sanofi Interview with Gary Nabel, SanofiSeptember 22, 2014Gary Nabel of Sanofi discusses recent licensing collaboration deals and the key attributes in terms of technology or culture that Sanofi looks for when considering a biotech collaboration. View session here View session here
Social media in the life sciences with Steve Dickman of CBT Advisors Social media in the life sciences with Steve Dickman of CBT AdvisorsSeptember 18, 2013Steve Dickman, CEO of CBT Advisors, recaps the BioPharm America 2013 panel discussion on social media in the life sciences, which featured fellow active users in the space. View session here View session here
A new era: Melding of drugs, devices and information A new era: Melding of drugs, devices and informationSeptember 17, 2013This discussion focuses on the use of technology to enhance the clinical and holistic well-being of individual patients, especially the geriatric population. View session here View session here
Academic Innovators™ Showcase at BioPharm America Academic Innovators™ Showcase at BioPharm AmericaSeptember 19, 2013This year at BioPharm America we launched our inaugural Academic Innovators Showcase to shine a spotlight on the many scientific advances with strong translational potential being made in the academic world. View session here View session here
Executive Interview with Robert Urban Executive Interview with Robert UrbanSeptember 17, 2013Robert Urban discusses how J&J's new Boston Innovation Center is a focal point for the company's engagement with early stage innovation. View session here View session here
Executive Interview with Jens Eckstein Executive Interview with Jens EcksteinSeptember 18, 2013The new approach to VC investing promises to move more companies to the winners circle and ultimately make drug portfolios stronger. View session here View session here
Early stage development: At the intersection of academic, biotech and pharma Early stage development: At the intersection of academic, biotech and pharmaSeptember 17, 2013Pharma and academia are collaborating to fill drug pipelines. Can they overcome key differences to make it work? Robin Wright interviews Erik Halvorsen at BioPharm America. View session here View session here
Leveraging big data to discover and develop breakthrough treatments Leveraging big data to discover and develop breakthrough treatmentsSeptember 17, 2013Big data is big news, but how can it be leveraged to discover and develop breakthrough treatments? Iya Khalil interviews Stanley Shaw about big data’s meaningful application. View session here View session here
Who will be funding early stage biotech in the future? Who will be funding early stage biotech in the future?September 18, 2013Luke Timmerman of Xconomy engages VCs on the outlook for future early stage investing and the pool of potential investors. View session here View session here
Personalized medicine: The path to broader adoption Personalized medicine: The path to broader adoptionSeptember 17, 2013What can we learn from the rare genetic disorder space and orphan drug space which are pioneering areas of personalized medicine? What R&D models will be necessary? View session here View session here
Interview with Garry Neil on TransCelerate BioPharma Interview with Garry Neil on TransCelerate BioPharmaSeptember 20, 2012Garry Neil explains the impetus behind and goals of TransCelerate BioPharma, a new nonprofit organization focused on accelerating the development of new medicines. View session here View session here
Interview with David de Graaf of Selventa Interview with David de Graaf of SelventaSeptember 20, 2012David de Graaf of Selventa is pioneering the development of a new class of innovative "Systems Diagnostics" for personalized medicine. View session here View session here
Interview with John Brooks, Joslin Diabetes Center Interview with John Brooks, Joslin Diabetes CenterSeptember 20, 2012John Brooks is positioning the Joslin Diabetes Center as the hub of innovation and research partnerships in diabetes. View session here View session here
Interview Jason Rhodes of Epizyme Interview Jason Rhodes of EpizymeSeptember 20, 2012Epizyme is aiming to create personalized therapeutics for patients with genetically-defined cancers using a branch of epigenetics called histone methyltransferases (HMTs) View session here View session here
Interview with Kevin Krenitsky of Foundation Medicine Interview with Kevin Krenitsky of Foundation MedicineSeptember 20, 2012Foundation Medicine is blazing new trails in personalized medicine for cancer patients. View session here View session here
From start-up to commercial company and the challenges in between: Could we do it again today? From start-up to commercial company and the challenges in between: Could we do it again today?September 20, 2012Karen Bernstein of BioCentury leads a discussion of the challenges in taking a company from start-up to commercial success. How is this different today than in years past? View session here View session here
Is there a downward trend in diabetes treatment innovation? And if so, what can we do about it? Is there a downward trend in diabetes treatment innovation? And if so, what can we do about it?September 20, 2012Diabetes continues, despite major treatment advances, to warrant new, novel therapies to further help patients gain better control of their disease. How are we doing? View session here View session here
Best deal structures: How do you operationalize external R&D?   Best deal structures: How do you operationalize external R&D? September 19, 2012There is no universally accepted model for externalizing R&D successfully and many key considerations to be weighed in how to create and operationalize these programs. View session here View session here
Emerging markets: Redefining global drug development strategy Emerging markets: Redefining global drug development strategySeptember 19, 2012Life science firms are rethinking the paradigms of global drug development due to growing market potential outside Western markets in emerging patient populations. View session here View session here
Fierce 15 revealed Fierce 15 revealedSeptember 19, 2012John Carroll, Editor of FierceBiotech, discusses the current landscape in life sciences with Fierce 15 CEOs. The 2012 Fierce 15 selection was revealed the week of the conference. View session here View session here
New financing models for creative exit strategies New financing models for creative exit strategiesSeptember 19, 2012Whether constructing new types of licensing deals or rethinking the corporate structure, companies hope to once again make private biotech companies attractive investments. View session here View session here
An exploration of new roles along the drug development value chain: Who’s in, who’s out, and are the new occupants positioned to succeed? An exploration of new roles along the drug development value chain: Who’s in, who’s out, and are the new occupants positioned to succeed?September 19, 2012New roles are being assumed along the drug development value chain. Who has vacated these roles? Are the new occupants positioned to succeed? View session here View session here
Arrow Up

Follow this event:
Sign up now
For news and updates

Privacy Policy and Cookies Terms of Use

Home | Contact Us | Site Map
See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2016 EBD Group
Privacy Policy and Cookies
Terms of Use